Class summary at a glance.

Every drug in the Angiotensin Converting Enzyme Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 5tracked in Part D
CY24 Part D spend: $36.4Mcombined across class
Total Rx claims: 2.5M772K unique beneficiaries
Generic mfrs (active): 19across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Ramipril

Brand: Vostally · 2.3M Part D claims (CY24) · 714K beneficiaries · First FDA approval: 2008-06-10

8 generic mfrs 0 plans require PA

Low NADAC$0.053

→

Avg plan cost$0.064

Part D spend $27.4M 1× spread, current vs floor

Class share

75%

of class CY24 spend

View profile →

Captopril

104K Part D claims (CY24) · 31K beneficiaries · First FDA approval: 1996-02-13

7 generic mfrs 0 plans require PA

Low NADAC$0.138

→

Avg plan cost$0.246

Part D spend $7.1M 2× spread, current vs floor

Class share

19%

of class CY24 spend

View profile →

Trandolapril

86K Part D claims (CY24) · 27K beneficiaries · First FDA approval: 2007-06-11

3 generic mfrs 0 plans require PA

Low NADAC$0.190

→

Avg plan cost$0.193

Part D spend $2.0M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Trandolapril Tablets

Brand: Trandolapril · — Part D claims (CY24) · First FDA approval: 2015-03-31

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Trandolapril and Verapamil

— Part D claims (CY24) · First FDA approval: 2015-02-25

1 generic mfrs 0 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.